The 8,200-store chain would expand to 11,000 locations operating in 10 countries, if shareholders approve.
The agreement between AbbVie and Express Scripts is seen as a seismic shift in the joint development of cost-effective therapies, and gives the new regimen a slight edge on Gilead's popular remedies.
The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
"The trouble is that the market is changing much faster than most marketers realize."
Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.
The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial
The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."
Canadian firm presents FDA with its third biosimilar application.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.
- Walgreen to vote on merger with Alliance Boots
- PBM deal on new hep.-C cocktail highlights drugmaker tolerance for discounts
- GSK shingles vax shaping up to compete with Merck's
- Five things for pharma marketers to know: Monday, December 22
- Five Big Shifts in Policy and Technology That Marketers Should Worry about in 2015